Bioventus Analyst Ratings
Bioventus Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/30/2022 | 32.98% | Goldman Sachs | $13 → $2.5 | Maintains | Neutral |
| 11/22/2022 | — | Craig-Hallum | Downgrades | Buy → Hold | |
| 11/10/2022 | 165.96% | Morgan Stanley | $11 → $5 | Maintains | Overweight |
| 11/09/2022 | — | Canaccord Genuity | Downgrades | Buy → Hold | |
| 11/09/2022 | — | JP Morgan | Downgrades | Overweight → Underweight | |
| 10/11/2022 | 485.11% | Morgan Stanley | $12 → $11 | Maintains | Overweight |
| 09/07/2022 | 591.49% | Goldman Sachs | $15 → $13 | Maintains | Neutral |
| 08/12/2022 | 538.3% | Morgan Stanley | $11 → $12 | Maintains | Overweight |
| 05/12/2022 | 485.11% | Morgan Stanley | $18 → $11 | Maintains | Overweight |
| 03/21/2022 | 804.26% | Goldman Sachs | $19 → $17 | Maintains | Neutral |
| 03/15/2022 | 1495.74% | Craig-Hallum | → $30 | Initiates Coverage On | → Buy |
| 03/11/2022 | 857.45% | Morgan Stanley | $20 → $18 | Maintains | Overweight |
| 11/15/2021 | 963.83% | Morgan Stanley | → $20 | Reinstates | → Overweight |
| 07/01/2021 | 910.64% | Goldman Sachs | $20 → $19 | Downgrades | Buy → Neutral |
| 04/19/2021 | 910.64% | Morgan Stanley | $18 → $19 | Maintains | Overweight |
| 03/08/2021 | 1123.4% | Canaccord Genuity | → $23 | Initiates Coverage On | → Buy |
| 03/08/2021 | 857.45% | Morgan Stanley | → $18 | Initiates Coverage On | → Overweight |
| 03/08/2021 | 804.26% | JP Morgan | → $17 | Initiates Coverage On | → Overweight |
| 03/08/2021 | 910.64% | Goldman Sachs | → $19 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 11/30/2022 | 32.98% | 高盛 | $13 → $2.5 | 維護 | 中性 |
| 11/22/2022 | — | 克雷格-哈勒姆 | 評級下調 | 購買→Hold | |
| 11/10/2022 | 165.96% | 摩根士丹利 | $11 → $5 | 維護 | 超重 |
| 11/09/2022 | — | 卡納科特·格納奇 | 評級下調 | 購買→Hold | |
| 11/09/2022 | — | 摩根大通 | 評級下調 | 增持→減持 | |
| 10/11/2022 | 485.11% | 摩根士丹利 | $12 → $11 | 維護 | 超重 |
| 09/07/2022 | 591.49% | 高盛 | $15 → $13 | 維護 | 中性 |
| 08/12/2022 | 538.3% | 摩根士丹利 | $11 → $12 | 維護 | 超重 |
| 05/12/2022 | 485.11% | 摩根士丹利 | $18 → $11 | 維護 | 超重 |
| 03/21/2022 | 804.26% | 高盛 | $19 → $17 | 維護 | 中性 |
| 03/15/2022 | 1495.74% | 克雷格-哈勒姆 | → $30 | 開始承保 | →購買 |
| 03/11/2022 | 857.45% | 摩根士丹利 | $20 → $18 | 維護 | 超重 |
| 11/15/2021 | 963.83% | 摩根士丹利 | → $20 | 恢復 | →超重 |
| 07/01/2021 | 910.64% | 高盛 | $20 → $19 | 評級下調 | 購買→中性 |
| 04/19/2021 | 910.64% | 摩根士丹利 | $18 → $19 | 維護 | 超重 |
| 03/08/2021 | 1123.4% | 卡納科特·格納奇 | → $23 | 開始承保 | →購買 |
| 03/08/2021 | 857.45% | 摩根士丹利 | → $18 | 開始承保 | →超重 |
| 03/08/2021 | 804.26% | 摩根大通 | → $17 | 開始承保 | →超重 |
| 03/08/2021 | 910.64% | 高盛 | → $19 | 開始承保 | →購買 |
What is the target price for Bioventus (BVS)?
Bioventus(BVS)的目標價格是多少？
The latest price target for Bioventus (NASDAQ: BVS) was reported by Goldman Sachs on November 30, 2022. The analyst firm set a price target for $2.50 expecting BVS to rise to within 12 months (a possible 32.98% upside). 12 analyst firms have reported ratings in the last year.
高盛於2022年11月30日報道了Bioventus(納斯達克代碼：BVS)的最新目標價。這家分析公司將目標價定為2.50美元，預計BVS將在12個月內升至(可能上漲32.98%)。去年有12家分析公司公佈了評級。
What is the most recent analyst rating for Bioventus (BVS)?
Bioventus(BVS)的最新分析師評級是多少？
The latest analyst rating for Bioventus (NASDAQ: BVS) was provided by Goldman Sachs, and Bioventus maintained their neutral rating.
高盛提供了對Bioventus(納斯達克代碼：BVS)的最新分析師評級，Bioventus維持中性評級。
When is the next analyst rating going to be posted or updated for Bioventus (BVS)?
Bioventus(BVS)的下一次分析師評級將於何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Bioventus, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Bioventus was filed on November 30, 2022 so you should expect the next rating to be made available sometime around November 30, 2023.
分析師在進行了廣泛的研究後得出了股票評級，其中包括查閲公共財務報表，與Bioventus的高管和客户交談，以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。Bioventus的上一次評級是在2022年11月30日提交的，所以你應該預計下一次評級將在2023年11月30日左右的某個時候提供。
Is the Analyst Rating Bioventus (BVS) correct?
分析師對Bioventus(BVS)的評級正確嗎？
While ratings are subjective and will change, the latest Bioventus (BVS) rating was a maintained with a price target of $13.00 to $2.50. The current price Bioventus (BVS) is trading at is $1.88, which is out of the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但最新的Bioventus(BVS)評級維持不變，目標價在13.00美元至2.50美元之間。Bioventus目前的交易價格為1.88美元，超出了分析師的預期區間。
譯文內容由第三人軟體翻譯。